Physician profile
Bashar S Alasad
NPI 1215988803
$2,224.30
in general payments reported to CMS, 2019-2025
36 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $160 · 2021: $35.85 · 2022: $111 · 2023: $684 · 2024: $570 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.59 |
| Education | $261.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $296.23 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $182.31 | 2019-2025 | |
| Janssen Biotech, INC. | $151.60 | 2019-2023 | Darzalex |
| Genzyme Corporation | $127.16 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $116.97 | 2020-2025 | Opdivo |
| Celgene Corporation | $108.12 | 2023-2024 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $102.53 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $101.65 | 2019-2023 | Keytruda, Lynparza |
| Genentech USA, INC. | $101.34 | 2022-2025 | Polivy, Lunsumio, Tecentriq |
| Sobi, INC | $94.38 | 2023-2025 | |
| Intuitive Surgical, INC. | $73.96 | 2025 | |
| Daiichi Sankyo INC. | $73.93 | 2024-2025 | Enhertu, Vanflyta |
| Abbvie INC. | $70.94 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $69.08 | 2023-2024 | Orgovyx |
| Incyte Corporation | $54.92 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.08 | 2023-2024 | Libtayo |
| Astellas Pharma US INC | $44.55 | 2023-2024 | Padcev |
| Seagen INC. | $38.74 | 2023 | Tukysa, Padcev |
| Eisai INC. | $35.91 | 2019-2023 | |
| Lilly USA, LLC | $34.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $33.10 | 2023-2025 | Imfinzi, Enhertu |
| Array Biopharma INC | $26.11 | 2025 | Mektovi, Braftovi, Lorbrena |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Blueprint Medicines Corporation | $21.92 | 2023 | Ayvakit |
| Stemline Therapeutics INC. | $20.37 | 2023 | Orserdu |
| Tersera Therapeutics LLC | $20.31 | 2023 | Zoladex |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.79 | 2022 | |
| Exelixis INC. | $19.39 | 2025 | Cabometyx |
| Geron Corporation | $17.89 | 2025 | Rytelo |
| Cti Biopharma Corp. | $15.76 | 2023 | Vonjo |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2019 | |
| Amgen INC. | $14.34 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Alasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.